Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis

Documenti analoghi

• Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma
  di: Nil Albiol, et al.
  Pubblicazione: (2026)
• High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
  di: Maeve A. O'Reilly, et al.
  Pubblicazione: (2024)
• Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
  di: Núria Martínez‐Cibrián, et al.
  Pubblicazione: (2025)
• Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK
  di: Andrea Kuhnl, et al.
  Pubblicazione: (2026)
• Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
  di: Arnon P. Kater, et al.
  Pubblicazione: (2024)